semaglutide from ro GLP-1 Medications for Weight Loss with the Body Program Important Safety Information for GLP-1s
Description
Your prescriber uses the T2D pathway, not the Bridge
They are acknowledged as a major scientific breakthrough
Clinical trial data from the SUSTAIN and STEP programs indicate that nausea, the most frequently reported side effect, generally improves within 46 weeks for most patients as tolerance develops
Some patients maintain weight successfully on 1.7 mg or 1.0 mg after reaching their target
Weeks five through twelve (5mg-7.5mg) This is where most researchers begin seeing meaningful results
However, you may not consciously notice this at first because the effect is subtle and dose-dependent
